Ashland: The Commercial Engine Works. One Plant Doesn't.

FY2027 guidance leans on Hopewell throughput and a pulled-forward CapEx bet on a coatings recovery that even the analysts on the call don't believe in yet.

ASH · Earnings Call · 2026-11-04

A good quarter with an awkward asterisk

Ashland closed fiscal 2026 with almost everything it can control working. Fourth-quarter sales rose 4% to $498M on 3% volume and 2% price; adjusted EBITDA added 2% to $121M; adjusted EPS ticked to $1.12 from $1.08. Life Sciences printed a record 35.6% adjusted EBITDA margin on $180M of sales, Personal Care crossed 30% for the first time in the company's modern configuration, and Intermediates eked out an 18.2% margin in a BDO market everyone describes as a trough. Then there is Specialty Additives: sales flat at $130M, EBITDA down to $20M from $29M. That single segment is why a CEO who spent the year celebrating commercial momentum opened with a hedge. “the quarter demonstrated strong underlying performance across much of the portfolio, while highlighting a clear opportunity to convert continued commercial momentum into stronger consolidated profitability through improved operating execution.” — Guillermo Novo, Chair and CEO · 2026-11-04 Read that sentence twice. It is the whole dossier in one line: the selling organisation is outperforming; the factories are not.

Hopewell is a one-plant problem wearing a segment's clothes

Ashland has been telling the market about Hopewell for at least three quarters. In July the CEO was already blunt about the mechanism: “Our biggest issue right now focusing on is Hopewell getting the productivity, and it is really kilos per hour production of a certain part of our product line.” — Guillermo Novo, Chairman and CEO · 2026-07-29 Nothing about the diagnosis changed this quarter — only the accounting of it became explicit. “we were under-absorbed versus our initial plan this year, about $17.5 million,” — William Whitaker, Chief Financial Officer · 2026-11-04 the CFO said, of which roughly $5M carries into the fiscal first quarter. Management expects to more than offset that across FY2027, with output up about 25% through 2028. The reason this matters more than the $5M is that it is the last remaining item on a list that used to have three entries. Calvert City ($15M) and weather ($5M) are lapped and normalised. Hopewell is the residual. Ashland has now spent two years as a company that rebuilt its portfolio, rationalised its footprint, and then discovered that the remaining assets had to actually run. The keyword history shows the migration: commercial execution was one of the company's fastest-rising themes in mid-2026 and is now among its sharpest decliners, while Hopewell output and Asset utilization moved up the ranking. The story stopped being about selling and started being about producing. Worth putting in context: the business that this drags on is not small. Total revenue has shrunk roughly 60% over ten years as Ashland sold adhesives, nutraceuticals and other pieces. High-teens operating margins are the reward for that surgery, and they are exactly what a Hopewell miss eats into.

The CapEx question nobody wanted to answer

Buried in the FY2027 guide is the item that actually got the Q&A heated: capital expenditure rising from roughly $90M to up to $140M, to pull forward debottlenecking originally slated for 2029-2030. The CEO's logic is pent-up housing and coatings demand. The buy-side logic was less charitable.

It just seemed like odd timing to be pulling forward for a Coatings recovery. No one seems super excited there at the moment.
Josh Spector, Analyst · 2026-11-04

The answer — that Ashland would rather be ready than rushed, and that the $140M is a ceiling rather than a plan — is reasonable but softer than the number. Watch the qualifiers: “it is an increase from $90 million-$140 million in the guide... We wanted to give ourselves some room on the project timing.” — William Whitaker, Chief Financial Officer · 2026-11-04 Note what this does to the free-cash-flow story. FY2026 conversion came in above the 50% commitment; FY2027 is guided to greater than 40%, with the CFO reiterating the longer-run 50% ambition. That is a deliberate step back for a company whose recent equity narrative has leaned on cash generation and deleveraging. Effective net cash sits at -$609M against 2.3x net leverage — comfortable, but no longer falling fast.

What management stopped talking about

The most informative silence this quarter is the sale process. An analyst asked directly, and the answer was the standard non-answer: “As usual, we don't comment on speculation and rumors and all the noise that is out there.” — Guillermo Novo, Chair and CEO · 2026-11-04 Compare that to July, when the same question produced a long, engaged riff on the Capital Allocation Advisory Committee and the two new Ancora-backed directors. The committee was a headline keyword in the third quarter; this quarter it is a footnote about being "very engaged." That is not a denial, but it is a change of register — and it lands against a chemicals tape where consolidation is being priced. The global keyword set is now carrying Olin Huntsman, a live merger narrative in the same specialty-chemicals neighbourhood, and reporters at both Olin and Huntsman flagged it this week. Ashland's portfolio — pharma excipients, personal care actives, coatings additives — is precisely the kind of sum-of-parts that attracts that logic. The other thing Ashland stopped emphasising is the external excuse. This quarter the CEO was unusually direct that the miss was internal, not macro, and that the transformation is finished: the portfolio is reset, the network is optimised, the innovation portfolio rebuilt. The Performance Specialties and Coatings businesses are growing 9% and 14% respectively into flat end markets, and Globalize plus Innovate delivered roughly $52M of incremental sales against a $35M target. That is genuinely good. The FY2027 guide of $405-435M EBITDA, however, is not asking the market to pay for good — it is asking the market to pay for fixed. Which is the trade. The stock is up 16% in ninety days into this print, having spent four years well below its 2022 high. Investors are not paying for the quarter that just happened; they are paying for a 25% throughput increase at one plant, a coatings recovery that may or may not arrive, and whatever the advisory committee eventually recommends. Two of those three are outside the company's control.